Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Baxter
Harvard Business School
Medtronic

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,105,788

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,105,788
Title:Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith
Abstract: Methods, systems, kits and assays for diagnosing, monitoring or screening for mucopolysaccharidosis (MPS) and methods and systems for assaying test compounds for therapeutic activity are described, whereby MPS marker protein levels are assayed as an indication of MPS.
Inventor(s): Clarke; Lorne A. (West Vancouver, CA), Randall; Derrick Raymond (Burnaby, CA), Sinclair; Graham (Victoria, CA)
Assignee: The University of British Columbia (Vancouver, CA)
Application Number:12/096,589
Patent Claims:1. A method of identifying a compound that promotes glycosaminoglycan (GAG) degradation, the method comprising: (1) (a) providing a cell having reduced enzyme activity resulting in accumulation of undegraded or partially degraded GAGs, wherein the enzyme is involved in degrading GAGs and contacting the cell with one or more test compounds; or (b) providing a mucopolysaccharidoses (MPS) experimental animal having reduced enzyme activity resulting in an accumulation of undegraded or partially degraded GAGs and administering to the experimental animal one or more test compounds; and (2) determining whether there is a relative increase or decrease of MPS marker as a result of the administration of one or more test compounds, whereby any compound that promotes GAG degradation is identified.

2. The method of claim 1, wherein MPS marker is selected from one or more of the following markers: Fibrinogen, .gamma.-polypeptide; Fibrinogen, .alpha.-polypeptide; .alpha.-1-antitrypsin 1-5; Inter-.alpha. trypsin inhibitor, heavy chain 1; Apolipoprotein B; Pzp protein; Gelsolin; Kininogen precursor; Histidine-rich glycoprotein; Alpha-1 proteinase inhibitor 2; Apolipoprotein C-III; Factor XIII beta; Paraoxonase 1; Heparin cofactor II thrombin complex (HCII-T); and Heparin cofactor II (HCII).

3. The method of claim 2, wherein the one or more test compounds increases HCII levels, or wherein the one or more test compounds decreases HCII-T levels.

4. The method of claim 1, further comprising administering any identified compound to a test subject.

5. The method of claim 1, further comprising incorporating any identified compound into a medicament.

6. A method for identifying an individual having mucopolysaccharidoses (MPS), or determining whether an individual is at risk for MPS, the method comprising: testing at least one biological sample from the individual in an MPS marker detection assay, operable for determining relative MPS marker levels, wherein an MPS marker level different from the MPS marker level in a normal subject is indicative of MPS status.

7. The method of claim 6, wherein MPS marker is selected from one or more of the following: Fibrinogen, .gamma.-polypeptide; Fibrinogen, .alpha.-polypeptide; .alpha.-1-antitrypsin 1-5; Inter-.alpha. trypsin inhibitor, heavy chain 1; Apolipoprotein B; Pzp protein; Gelsolin; Kininogen precursor; Histidine-rich glycoprotein; Alpha-1 proteinase inhibitor 2; Apolipoprotein C-III; Factor XIII beta; Paraoxonase 1; Heparin cofactor II thrombin complex (HCII-T), and Heparin cofactor II (HCII).

8. The method of claim 6, wherein the MPS marker is HCII, and a decreased HCII level is indicative of MPS, or wherein the MPS marker is HCII-T, and an increased HCII-T level is indicative of MPS.

9. The method of claim 6, further comprising administering a treatment to the subject identified as having MPS or at risk for MPS.

10. The method of claim 9, wherein the treatment comprises Aldurazyme.RTM. (laronidase) administration.

11. The method of claim 9, wherein the treatment comprises a bone marrow transplant.

12. The method of claim 9, wherein the biological sample is collected one or more times prior to, during or after treatment.

Summary for Patent:   Start Trial

PCT Information
PCT FiledDecember 08, 2006PCT Application Number:PCT/CA2006/002011
PCT Publication Date:June 14, 2007PCT Publication Number:WO2007/065273

Details for Patent 8,105,788

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biomarin ALDURAZYME laronidase VIAL 125058 001 2003-04-30   Start Trial The University of British Columbia (Vancouver, CA) 2039-03-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Colorcon
McKesson
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.